Subtypes of renal tumors in kidney cancer patients have different genetic backgrounds, prognoses, and responses to surgical and medical treatment, and their differential diagnosis is a frequent challenge.

mi-KIDNEY provides that differential diagnosis with fast, standardized, and subjective classification. This molecular diagnostic test serves clinicians by differentiating the 4 main histological types of primary kidney tumors: benign oncocytoma and the 3 most common subtypes of renal cell carcinomas: clear cell, papillary, and chromophobe1.

Accurately classifies the four most common kidney tumors: benign oncocytoma, clear cell, papillary, and chromophobe1

Provides definitive results on kidney biopsies to avoid unnecessary surgeries

Overall accuracy of 95%1

Rapid turnaround time of 4-7 days

Evidence
Evidence

Read Studies About mi-KIDNEY

Spector Y, Fridman E, Rosenwald S, et al. Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol. 2013;7(3):732-738.

Fridman E, Dotan Z, Barshack I, et al. Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression. J Mol Diagn. 2010;12(5):687-696.

References

  1. Spector Y, Fridman E, Rosenwald S, et al. Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol. 2013;7(3):732-738.